Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Neuropharmacology

• Publication date

  2011-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.neuropharm.2011.08.034PMID 21903115
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression.

  2011cited by this paper
• Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure.

  2011cited by this paper
• The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder.

  2011cited by this paper
• Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression.

  2010cited by this paper
• On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039

  2010cited by this paper
• From synapse to nucleus: novel targets for treating depression.

  2010cited by this paper
• mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

  2010influential reference
• Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

  2009cited by this paper
• mGluR-Dependent Long-Term Depression Is Associated with Increased Phosphorylation of S6 and Synthesis of Elongation Factor 1A but Remains Expressed in S6K-Deficient Mice

  2008cited by this paper
• Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

  2008influential reference
• Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

  2008cited by this paper
• Dysregulated Metabotropic Glutamate Receptor-Dependent Translation of AMPA Receptor and Postsynaptic Density-95 mRNAs at Synapses in a Mouse Model of Fragile X Syndrome

  2007cited by this paper
• The selectivity of protein kinase inhibitors: a further update.

  2007cited by this paper
• A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

  2006cited by this paper
• Ketamine Produces Lasting Disruptions in Encoding of Sensory Stimuli

  2006cited by this paper
• An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats

  2006cited by this paper
• AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist.

  2005influential reference
• The tail suspension test: A new method for screening antidepressants in mice

  2004cited by this paper
• MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity.

  2004cited by this paper
• Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.

  2004cited by this paper
• Prolonged effect of an anesthetic dose of ketamine on behavioral despair.

  2002influential reference
• Antidepressant effects of ketamine in depressed patients.

  2000cited by this paper
• 2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.

  1998cited by this paper

• Lysergic acid diethylamide pretreatment prolongs brain-stimulation induced neural activity changes

  2026cites this paper
• From Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation

  2025influential citation
• Modulation of Metabotropic Glutamate Receptors as a Strategy to Improve the Efficacy and Safety of Ketamine as an Antidepressant

  2025cites this paper
• Mechanism of antidepressant action of ketamine and differences between its two enantiomers

  2025cites this paper
• Two polygenic mouse models of major depressive disorders identify TMEM161B as a potential biomarker of disease in humans

  2024cites this paper
• mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development

  2023cites this paper
• Beneficial effects of physical exercise and an orally active mGluR2/3 antagonist pro-drug on neurogenesis and behavior in an Alzheimer's amyloidosis model

  2023cites this paper
• Role of mTOR1 signaling in the antidepressant effects of ketamine and the potential of mTORC1 activators as novel antidepressants.

  2022cites this paper
• Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.

  2022cites this paper
• Are mGluR2/3 Inhibitors Potential Compounds for Novel Antidepressants?

  2022cites this paper
• Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants.

  2022cites this paper
• Orally active mGluR2/3 metabotropic antagonist pro-drug mimics the beneficial effects of physical exercise on neurogenesis, behavior, and exercise-related molecular pathways in an Alzheimer’s disease mouse model

  2022cites this paper
• Effects of Chronic LY341495 on Hippocampal mTORC1 Signaling in Mice with Chronic Unpredictable Stress-Induced Depression

  2022influential citation
• The role of mGlu2/3 receptor antagonists in the enhancement of the antidepressant-like effect of ketamine.

  2022cites this paper
• The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice.

  2021cites this paper
• Perisynaptic astrocytes as a potential target for novel antidepressant drugs.

  2021cites this paper
• Disease Modification in Epilepsy: Behavioural Accompaniments.

  2021cites this paper
• Antidepressant-like effect of guanosine involves activation of AMPA receptor and BDNF/TrkB signaling

  2021cites this paper
• Evaluation of the Safety, Tolerability, and Pharmacokinetic Profiles of TP0473292 (TS-161), A Prodrug of a Novel Orthosteric mGlu2/3 Receptor Antagonist TP0178894, in Healthy Subjects and Its Antidepressant-Like Effects in Rodents

  2021cites this paper
• mGlu2/3 Receptor Antagonists as Rapid-Acting Antidepressants

  2021cites this paper
• Advances in novel molecular targets for antidepressants.

  2020cites this paper
• Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review

  2020cites this paper
• Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery

  2020cites this paper
• mTORC1-dependent signaling pathway underlies the rapid effect of creatine and ketamine in the novelty-suppressed feeding test.

  2020cites this paper
• Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine

  2020cites this paper
• mGlu2/3 receptor as a novel target for rapid acting antidepressants.

  2020cites this paper
• AMPA receptor-mTORC1 signaling activation is required for neuroplastic effects of LY341495 in rat hippocampal neurons

  2020cites this paper
• mGlu2/3 receptor antagonism: A mechanism to induce rapid antidepressant effects without ketamine-associated side-effects.

  2020cites this paper
• The effect of mGlu2/3 receptors on synaptic activities to different types of GABAergic interneurons in the anterior cingulate cortex.

  2020cites this paper
• Rapid acting antidepressants in the mTOR pathway: current evidence.

  2020cites this paper
• Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective

  2019cites this paper
• mGlu2/3 receptor antagonists.

  2019cites this paper
• Role of Serotonergic System in the Antidepressant Actions of mGlu2/3 Receptor Antagonists: Similarity to Ketamine

  2019cites this paper
• Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats.

  2019cites this paper
• mGlu2 and mGlu3 Negative Allosteric Modulators Divergently Enhance Thalamocortical Transmission and Exert Rapid Antidepressant-like Effects.

  2019cites this paper
• Targeting of Metabotropic Glutamate Receptors for the Development of Novel Antidepressants

  2019cites this paper
• Animal models of major depressive disorder and the implications for drug discovery and development

  2019cites this paper
• Group II metabotropic glutamate receptor blockade promotes stress resilience in mice

  2019cites this paper
• Role of BDNF in the pathophysiology and treatment of depression: Activity‐dependent effects distinguish rapid‐acting antidepressants

  2019cites this paper
• Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.

  2019cites this paper
• Neurobiology of rapid acting antidepressants: convergent effects on GluA1-synaptic function

  2019cites this paper
• The novel methoxetamine analogs N-ethylnorketamine hydrochloride (NENK), 2-MeO-N-ethylketamine hydrochloride (2-MeO-NEK), and 4-MeO-N-ethylketamine hydrochloride (4-MeO-NEK) elicit rapid antidepressant effects via activation of AMPA and 5-HT2 receptors

  2019cites this paper
• The Effect of Glutamatergic Modulators on Extracellular Glutamate: How Does this Information Contribute to the Discovery of Novel Antidepressants?

  2019cites this paper
• Rapid-acting antidepressants.

  2019cites this paper
• The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug

  2018cites this paper
• Convergent Mechanisms Underlying Rapid Antidepressant Action

  2018cites this paper
• 5‐HT1A receptor stimulation in the medial prefrontal cortex mediates the antidepressant effects of mGlu2/3 receptor antagonist in mice

  2018influential citation
• Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (R)-Ketamine in a Social Defeat Stress Model.

  2018cites this paper
• Pharmacological interaction of Galphimia glauca extract and natural galphimines with Ketamine and Haloperidol on different behavioral tests.

  2018cites this paper
• mGlu receptors as potential targets for novel antidepressants

  2018cites this paper
• Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide

  2018cites this paper
• Exploring the neuropsychiatric spectrum using high-content functional analysis of single-cell signaling networks

  2018cites this paper
• Rapid-Acting Antidepressants.

  2018cites this paper
• Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date

  2018cites this paper
• Pharmacological properties and innovative therapeutic targets of novel compounds used to treat major depression

  2018cites this paper
• Identifying fast-onset antidepressants using rodent models

  2017cites this paper
• Beyond Ketamine: New Approaches to the Development of Safer Antidepressants

  2017cites this paper
• Role of 5-HT1A Receptor Stimulation in the Medial Prefrontal Cortex in the Sustained Antidepressant Effects of Ketamine

  2017cites this paper
• mGlu2/3 Receptor Antagonists as Novel Antidepressants.

  2017cites this paper
• 4/25/16 Running head: ANTIDEPRESSANT EFFECTS OF KETAMINE The Antidepressant Effects of Ketamine in Wistar and Sprague Dawley Rats

  2016cites this paper
• Metabotropic Glutamate Receptors in Central Nervous System Diseases.

  2016cites this paper
• Behavioral, neurochemical and molecular changes after acute deep brain stimulation of the infralimbic prefrontal cortex.

  2016cites this paper
• Role of calcium, glutamate and NMDA in major depression and therapeutic application.

  2016cites this paper
• The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN

  2016cites this paper
• Fast-acting antidepressants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures.

  2016influential citation
• Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies

  2016cites this paper
• Ketamine ’ s Legacy : New Targets for the Development of Rapid onset Antidepressant Drugs

  2016cites this paper
• Glutamate-Based Drug Discovery for Novel Antidepressants

  2016cites this paper
• A novel pipeline for drug discovery in neuropsychiatric disorders using high-content single-cell screening of signalling network responses ex vivo

  2016cites this paper
• グループII mGlu 受容体拮抗薬の抗うつ作用：mTOR シグナルおよびセロトニン神経系の関与

  2016cites this paper
• Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

  2016cites this paper
• The Role of mTOR in Mood Disorders Pathophysiology and Treatment

  2016cites this paper
• Group II mGlu receptor antagonist LY341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats

  2016influential citation
• The antidepressant effects of ketamine and the underlying mechanisms

  2015cites this paper
• Prenatal chronic mild stress induces depression-like behavior and sex-specific changes in regional glutamate receptor expression patterns in adult rats.

  2015cites this paper
• Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2.

  2015cites this paper
• Sex-specific increase in susceptibility to metabolic syndrome in adult offspring after prenatal ethanol exposure with post-weaning high-fat diet

  2015cites this paper
• Ketamine uropathy: Hong Kong experience

  2015cites this paper
• Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 – present)

  2015cites this paper
• Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants

  2015cites this paper
• mTOR signaling in the neuropathophysiology of depression: current evidence

  2015cites this paper
• Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents.

  2015cites this paper
• Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections

  2014cites this paper
• Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test

  2014cites this paper
• Antidepressant-like effect of ascorbic acid is associated with the modulation of mammalian target of rapamycin pathway.

  2014cites this paper
• The peptidic antidepressant spadin interacts with prefrontal 5-HT4 and mGluR2 receptors in the control of serotonergic function

  2014cites this paper
• Signaling pathways involved in antidepressant-induced cell proliferation and synaptic plasticity.

  2014cites this paper
• Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats.

  2014cites this paper
• Targeting of NMDA receptors in the treatment of major depression.

  2014cites this paper
• Cognitive Enhancers (Nootropics). Part 1: Drugs interacting with Receptors. Update 2014

  2014cites this paper
• Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats.

  2014influential citation
• Effect of an mGlu2/3 receptor antagonist on depressive behavior induced by withdrawal from chronic treatment with methamphetamine.

  2013cites this paper
• From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders.

  2013cites this paper
• Leading compounds for the validation of animal models of psychopathology

  2013cites this paper
• mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants.

  2013cites this paper
• Synaptic plasticity in depression: molecular, cellular and functional correlates.

  2013cites this paper
• mTOR complexes in neurodevelopmental and neuropsychiatric disorders

  2013cites this paper
• mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy.

  2013cites this paper
• Acute BDNF Treatment Upregulates GluR1-SAP97 and GluR2-GRIP1 Interactions: Implications for Sustained AMPA Receptor Expression

  2013cites this paper
• Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses.

  2013cites this paper